Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Schulder

Neurological Surgery Newark, NJ Medical Doctor

NPI 1619902400 CMS profile 254983

30 Bergen St, Admc 12 1205, Newark, NJ 07107

Open in the dashboard

General payments

$55,057

29 records reported · program years 2019–2025

Research payments

$6,517

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$95,342 paid to institutions, not to them · program years 2020–2024

Through program year 2025, Michael Schulder of Newark, NJ is reported in the CMS Open Payments database as having received $55,057 across 29 general payments and $6,517 in research payments paid to them. Separately, studies naming them as principal investigator received $95,342 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 87th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $395 2
2024 General $5,669 9
2023 General $237 2
2022 General $177 1
2021 General $41,652 5
2020 General $6,400 3
2020 Research $2,333 2
2019 General $526 7
2019 Research $4,184 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Schulder
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Michael Schulder were reported at $395. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Michael Schulder Neurological Surgery median Middle half National median
2019 $526 $582 $138–$3,006 $163
2020 $6,400 $294 $76–$2,174 $114
2021 $41,652 $387 $105–$2,432 $132
2022 $177 $542 $139–$2,989 $149
2023 $237 $534 $145–$2,697 $160
2024 $5,669 $574 $155–$3,046 $164
2025 $395 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Hyperfine Operations, Inc. $40,000 1 payment
  2. Medtronic USA, Inc. $4,034 5 payments
  3. Elekta Solutions AB $2,430 1 payment
  4. Varian Medical Systems, Inc. $2,000 1 payment
  5. Accuray Incorporated $1,767 3 payments
  6. Stryker Corporation $1,570 5 payments
  7. Carl Zeiss Meditec USA, Inc. $1,500 2 payments
  8. Zap Surgical Systems, Inc. $800 2 payments
  9. Abbott Laboratories $215 3 payments
  10. Omniscient Neurotechnology America Ltd $177 1 payment
  11. Other $564 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $41,000 2 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,330 5 payments
  3. Food and Beverage $1,789 17 payments
  4. Travel and Lodging $1,438 4 payments
  5. Honoraria $500 1 payment
Products named General payments · program years 2019–2025
  1. Swoop $40,000 1 payment
  2. CYBERKNIFE SYSTEM $1,672 2 payments
  3. INTRABEAM $1,500 2 payments
  4. Zap-X $500 1 payment
  5. UNIVERSAL NEURO $365 2 payments
  6. ZAP-X MV IMAGER $300 1 payment
  7. ZAP-X TREATMENT PLANNING SOFTWARE $300 1 payment
  8. ZAP-X TREATMENT DELIVERY SOFTWARE $300 1 payment
  9. ZAP-X RADIOSURGERY SYSTEM $300 1 payment
  10. INFINITY $188 2 payments
  11. Other $900 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Arbor Pharmaceuticals, Inc. $6,517 5 payments

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$99,644

Medicare's payments for the services billed

Medicare patients

142

Average age 73

Services billed

309

85 women, 57 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 37%
Ischemic heart disease 34%
Depression 25%
Cancer 23%
COPD 20%
Chronic kidney disease 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

34 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record